Product Description
Mechanisms of Action: Cystine Amino Acid precusor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Brazil | Chile | China | Egypt | France | Hong Kong | India | Indonesia | Italy | Korea | Lebanon | Luxembourg | Malaysia | Morocco | Portugal | Russia | Serbia | Spain | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: A/Prof Gary Richardson
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Autism Spectrum Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
01291001F | P2 |
Completed |
Autism Spectrum Disorder |
2016-10-01 |